ID   BC-2
AC   CVCL_1856
SY   BC2
DR   BTO; BTO:0002721
DR   CLO; CLO_0001889
DR   EFO; EFO_0002045
DR   ATCC; CRL-2231
DR   BioSample; SAMN03471845
DR   BioSamples; SAMEA365820
DR   BioSamples; SAMEA365831
DR   Cosmic; 1238076
DR   Cosmic; 1515187
DR   Cosmic; 1588557
DR   DSMZ; ACC-678
DR   GDSC; 1295743
DR   GEO; GSM38794
DR   GEO; GSM38795
DR   GEO; GSM634732
DR   GEO; GSM710418
DR   GEO; GSM710434
DR   IGRhCellID; BC2
DR   LINCS_LDP; LCL-1957
DR   PharmacoDB; BC2_78_2019
DR   Wikidata; Q54795187
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RX   PubMed=7670109;
RX   PubMed=15613351;
RX   PubMed=20215515;
RX   PubMed=21685375;
WW   http://www.cells-talk.com/index.php/page/copelibrary?key=BC-2
CC   Doubling time: ~50-70 hours (DSMZ).
CC   Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
CC   Transformant: NCBI_TaxID; 37296; Human herpesvirus 8 (HHV-8/KSHV).
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis.
CC   Derived from sampling site: Pleural effusion.
ST   Source(s): ATCC; DSMZ
ST   Amelogenin: X,Y
ST   CSF1PO: 10,12
ST   D13S317: 11,12
ST   D16S539: 11,12
ST   D5S818: 11,13
ST   D7S820: 8,9
ST   TH01: 7
ST   TPOX: 10,11
ST   vWA: 14,19
DI   NCIt; C6915; Primary effusion lymphoma
DI   ORDO; Orphanet_48686; Primary effusion lymphoma
OX   NCBI_TaxID=9606; ! Homo sapiens
SX   Male
AG   31Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 12-03-20; Version: 20
//
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RA   Drexler H.G.;
RT   "The leukemia-lymphoma cell line factsbook.";
RL   (In) ISBN 9780122219702; pp.1-733; Academic Press; London (2001).
//
RX   PubMed=7670109; DOI=10.1182/blood.V86.7.2708.2708;
RA   Cesarman E., Moore P.S., Rao P.H., Inghirami G., Knowles D.M.,
RA   Chang Y.;
RT   "In vitro establishment and characterization of two acquired
RT   immunodeficiency syndrome-related lymphoma cell lines (BC-1 and BC-2)
RT   containing Kaposi's sarcoma-associated herpesvirus-like (KSHV) DNA
RT   sequences.";
RL   Blood 86:2708-2714(1995).
//
RX   PubMed=15613351; DOI=10.1128/JVI.79.2.1244-1251.2005;
RA   Fan W., Bubman D., Chadburn A., Harrington W.J. Jr., Cesarman E.,
RA   Knowles D.M.;
RT   "Distinct subsets of primary effusion lymphoma can be identified based
RT   on their cellular gene expression profile and viral association.";
RL   J. Virol. 79:1244-1251(2005).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=21685375; DOI=10.1182/blood-2010-12-323659;
RA   Roy D., Sin S.-H., Damania B., Dittmer D.P.;
RT   "Tumor suppressor genes FHIT and WWOX are deleted in primary effusion
RT   lymphoma (PEL) cell lines.";
RL   Blood 118:E32-E39(2011).
//